Algorae Pharmaceuticals Ltd
Company Profile
Business description
Algorae Pharmaceuticals Ltd is a clinical-stage pharmaceutical company developing transformative solutions for under met medical needs in the community. The firm develops AlgoraeOS, a closed-loop platform, leveraging computational tools to generate novel insights in silico that are being developed to initiate or accelerate therapeutic programs. The products of the company comprise AI-116, a novel combination drug candidate of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. The company is conceptualized to be a potential treatment for dementia, including Alzheimer’s disease, NTCELL is an alginate-coated capsule containing clusters of neonatal porcine choroid plexus cells. It also offers LP-003 Anti-obesity Drug and LC-002 migraine treatment.
Contact
525 Collins Street
Level 23, Rialto South Tower
MelbourneVIC3000
AUST: +61 422180317
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
48
Stocks News & Analysis
stocks
Fears of deteriorating loan quality sends bank share plummeting
stocks
Why it’s not all bad news for Flight Centre following downgrade
stocks
Chart of the Week: What 650 IPOs reveal about long-term performance
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,955.70 | 9.70 | -0.11% |
| CAC 40 | 8,431.61 | 46.12 | 0.55% |
| DAX 40 | 24,994.83 | 254.47 | 1.03% |
| Dow JONES (US) | 51,920.62 | 71.72 | 0.14% |
| FTSE 100 | 10,529.89 | 68.26 | 0.65% |
| HKSE | 23,076.91 | 335.27 | -1.43% |
| NASDAQ | 25,358.60 | 118.03 | -0.46% |
| Nikkei 225 | 70,193.86 | 2,172.48 | -3.00% |
| NZX 50 Index | 13,491.89 | 1.16 | -0.01% |
| S&P 500 | 7,357.49 | 0.73 | -0.01% |
| S&P/ASX 200 | 8,754.70 | 9.30 | -0.11% |
| SSE Composite Index | 4,120.28 | 9.47 | 0.23% |